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Abstract
Background: In low-income countries (LICs), HIV sentinel surveillance surveys (HIV-SSS) are recommended in between
two demographic and health surveys, due to low-cost than the latter. Using the classical unlinked anonymous testing
(UAT), HIV-SSS among pregnant women raised certain ethical and financial challenges. We therefore aimed at
evaluating how to use prevention of mother-to-child transmission of HIV (PMTCT) routine data as an alternative
approach for HIV-SSS in LICs.
Methods: A survey conducted through 2012 among first antenatal-care attendees (ANC1) in the ten regions of
Cameroon. HIV testing was performed at PMTCT clinics as-per the national serial algorithm (rapid test), and PMTCT site
laboratory (PMTCT-SL) performances were evaluated by comparison with results of the national reference laboratory
(NRL), determined as the reference standard.
Results: Acceptance rate for HIV testing was 99%, for a total of 6521 ANC1 (49 · 3% aged 15–24) enrolled nationwide.
Among 6103 eligible ANC1, sensitivity (using NRL testing as the reference standard) was 81 · 2%, ranging from 58 · 8%
(South region) to 100% (West region); thus implying that 18 · 8% HIV-infected ANC1 declared HIV-negative at the
PMTCT-SL were positive from NRL-results. Specificity was 99 · 3%, without significant disparity across sites. At
population-level, this implies that every year in Cameroon, ~2,500 HIV-infected women are wrongly declared
seronegative, while ~1,000 are wrongly declared seropositive. Only 44 · 4% (16/36) of evaluated laboratories
reached the quality target of 80%.
Conclusions: The study identified weaknesses in routine PMTCT HIV testing. As Cameroon transitions to using
routine PMTCT data for HIV-SSS among pregnant women, there is need in optimizing quality system to ensure
robust routine HIV testing for programmatic and surveillance purposes.
Background
Cameroon is a low-income country (LIC) of the central
Africa region, with an estimated population of 19 · 4 mil-
lion inhabitants in 2010 and a generalized epidemiology
of human immunodeficiency virus (HIV) in the general
population (4 · 3% prevalence) [1, 2]. In a context of
generalized HIV epidemic coupled with limited resources,
demographic and health surveys (DHS) represent a key
component for epidemic surveillance. However, be-
cause DHS are of important financial resources for
LICs, such surveys are recommended by the world
health organization (WHO) on 5 years intervals [3–5].
Of note, the epidemiological surveillance component of
HIV, of acquired immunodeficiency syndrome (AIDS)
and of sexually transmitted infections (STI) aims at
guiding control strategies against the AIDS pandemics,
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by providing reliable evidence on the burden and the
geographical distribution of infection. Data from such
surveys are essential for planning, implementation,
monitoring and evaluation of preventive, management,
and attenuation of the epidemiological impact within
specific settings [3].
Between two DHS, the trends of HIV prevalence in
the population are assessed through sentinel surveillance
surveys (SSS) conducted every 2 years among sub-popu-
lations. Particularly, the sub-population of first antenatal
care attendees (ANC1) represents a suitable target, as-per
WHO guidelines [3]. In this target population, HIV-SSS is
based on unlinked anonymous testing (UAT) wherein left-
over bloods from pregnant women are tested to determine
HIV prevalence in this population. Due to financial chal-
lenges in conducting SSS, the frequency of such surveys
remains low in several LICs (i.e. only two surveys con-
ducted in Cameroon after 13 years: in 2000 and 2009) [6].
Moreover, HIV-SSS among ANC1, in its classical model
of UAT, raises certain ethical concerns in that it does not:
(a) obtain informed consent from pregnant women tested
for HIV in the context of surveillance, (b) provide them
their surveillance HIV test results to those women, and (c)
refer them to available HIV care, treatment, and preven-
tion of mother to child transmission (PMTCT) services if
surveillance HIV test results are positive [6]. Additionally,
this HIV-SSS model also raises challenges in data
standardization and in designing reliable epidemiological
surveillance models for LICs [3, 6].
As PMTCT programs expand in coverage and capture
socio-demographic, syphilis, and HIV testing data simi-
lar to those collected by SSS, many countries are transi-
tioning to using routinely collected PMTCT program
data to replace UAT-based HIV-SSS. Studies conducted
in sub-Saharan Africa (Kenya in 2003, Botswana and
Uganda in 2005, Zimbabwe in 2007, Senegal in 2008,
and recently Mozambique in 2013) have shown evidence
of consistency between HIV-SSS data and routine PMTCT
program data. Factors favoring the suitability of PMTCT
program data were high ANC coverage, high acceptance in
HIV testing, and high-quality data in PMTCT registers
and in laboratory records [7–11]. In the same line,
India, Thailand and Rwanda used routine PMTCT data
for HIV-SSS or for providing epidemiological information
to strengthen surveillance [12–15]. Studies conducted in
Cameroon in 2003 and in 2007 reported HIV prevalence
data from PMTCT programs to be similar to surveillance
estimates and potentially reliable for monitoring the epi-
demic, provided there is good site laboratory performance
and high acceptance for HIV testing in ANC [6, 16].
However, Marsh et al., showed in 2010 that there were
substantial gaps in the quality of routine data and test-
ing that need to be addressed during transition [17]. In
accordance with WHO-guidelines [3], and considering
the ongoing program on strengthening laboratories cap-
acity for HIV testing (supported by the Centre for Disease
Control and prevention [CDC]), and lessons from previ-
ous studies, it was deemed relevant to perform a more
comprehensive study to identify routine PMTCT HIV
testing quality gaps, and quality strengthening strategies
to support transition to a PMTCT-based system of
HIV-SSS among pregnant women.
In Cameroon, PMTCT services are available in all 182
health districts and in 81% ANC sites (1674/2067); ANC
attendance is 42% and registers are standardized with
relevant information for HIV-SSS [18]. Thus, envisaging
PMTCT data for estimating HIV prevalence among ANC1
seems rationale [17–20]. We aimed at identifying PMTCT
quality gaps and strengthening measures that will ensure a
successful transition to using routine PMTCT data for
HIV-SSS in Cameroon. Specifically, we aimed at assessing
the acceptance rates of HIV testing at ANC clinics, the
intrinsic (sensitivity, specificity) and extrinsic (positive
predictive value [PPV], negative predictive value [NPV])
performances of HIV testing at PMTCT-site laboratories
(SLs) compared to reports from the National Reference




A prospective study was conducted through 2012 in the
ten regions of Cameroon, covering 20 SSS sites that in-
clude 60 SSS routine collection points. PMTCT sites were
chosen based on their localization (urban and rural repre-
sentation for each region of the country), coverage of
ANC1 in the catchment area (≥60%, as recommended by
the WHO), ANC client volume (ability to enroll ≥300–
500 pregnant women at ANC1 during the study period
of ≈ 3 months); and presence of ANC and PMTCT ser-
vices [3]. Urban regions had one site while rural regions
had three. In each selected site, pregnant women at-
tending their first ANC (ANC1) aged 15–49 were con-
secutively enrolled, until achieving the required site
sample size (i.e. 300 or 500 ANC1 per site), calculated
based on assumed site prevalence and a desired preci-
sion of 95% [3].
Procedure for sample collection and HIV testing
Plasma samples and sociodemographic data were collected
without altering the site routine functionality. During the
study period, HIV and syphilis screening were proposed to
ANC1 attendees according to routine procedure. HIV and
syphilis screening were then performed on-site, and only
syphilis result was delivered according to the classical SSS
procedure [3]. After HIV and syphilis testing on-site at
ANC1, residual plasma were transferred into cryotubes
that were marked with the ID code, and stored at 0°–8 °C.
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Plasma and form, linked by the ID code, were then per-
manently delinked from corresponding woman. Only
delinked samples were then taken to the central level
(NRL) as-per universal standards for transport of plasma
specimens [19].
A serial algorithm for HIV screening was used in all the
PMTCT-SLs and at the NRL, in conformity with the na-
tional algorithm for voluntary HIV testing (Fig. 1). Briefly,
the first test was Determine HIV1/2 (Abbott, Minato-ku-
Tokyo, Japan); in case of reactivity of this screening test,
Hexagon (Kora Healthcare, Ireland, United Kingdom) was
used as the confirmatory test. PMTCT-SLs and the NRL
received test kits of the same lot that were evaluated
through the on-going CDC quality assurance (QA)
strengthening program. At the PMTCT-SL, indeterminate
HIV results were reported as indeterminate by the re-
spective site, and were then referred to a tiebreaker test at
the level of the NRL; however tiebreaker results were not
available the same day and so were not recorded on the
surveillance form. Specimens tested at the NRL with inde-
terminate HIV results were subjected to an immediate
tiebreaker test, Oraquick (OraSure Technologies, Inc,
Bethlehem, Pennsylvania). Residual plasma from all ANC1
was stored at−70 °C in the NRL for quality control or fu-
ture testing. NRL test result was linked back to the infor-
mation from the surveillance form through the unique
identifiers to create a full data set for analysis.
Quality assurance of HIV surveillance survey
QA measures were implemented to ensure the quality of
surveillance procedures. Staff involved in surveillance
(including ANC/PMTCT site clinical and laboratory staff,
and central/regional surveillance supervisors) received
pre-survey training on the following: data recording in
ANC registers and SSS sheets; standard operating proce-
dures for HIV testing; study monitoring, data verification,
and sample shipment to NRL. Most PMTCT-SLs were
participating in a program for strengthening laboratories
capacity on HIV testing, coordinated by the CDC through
the use of dry tube specimens; with 100% concordance
generally recorded in HIV testing performance. The
survey supervisors routinely performed data verification/
validation on-site by comparing SSS sheets to ANC regis-
ters for accurate data collection. At the central level, data
were double entered using CSPro (Census and Survey
Processing) version 4 · 1 to minimize errors. Criteria for
excluding a sample from the overall analyses were based
on unavailable or unreadable or indeterminate results
from PMTCT-SL.
Quality assurance in proficiency testing
The Chantal BIYA International Reference Centre (CIRCB)
for research on HIV/AIDS prevention and management
(Yaounde, Cameroon) was selected as the NRL following a
series of rigorous performance evaluation with external
quality control before the survey and then three times dur-
ing the study, by the CDC-accredited laboratory. CIRCB
was then retained as NRL based on the required perform-
ance of 100% concordance in all four HIV testing panels
(dry tube specimens).
Performance of routine PMTCT-SL in HIV testing was
calculated using NRL results as gold standard. Based on
Fig. 1 National Algorithm for HIV rapid testing for voluntary and free counseling
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conclusive HIV results (i.e. negative or positive) obtained
after test 1 and test 2 (n = 6056) by both PMTCT-SLs and
the NRL, intrinsic (sensitivity and specificity) and extrinsic
(positive [PPV] and negative [NPV] predictive values) per-
formances were calculated, as shown in Table 1 [21]. To
mitigate potential sources of bias, all PMTCT-SL indeter-
minate results were excluded from all analyses performed
in the survey (both comparisons of individual test results
and comparisons of prevalence).
Ethical considerations
Ethical clearance for the study was obtained from the
Cameroon National Ethics Committee. The privacy of
consenting pregnant women and their data confidential-
ity were ensured through a permanent delinking process
that does not allow HIV test results to be traced back to
any personal identifying information. Data integrity was
assured by a double entry and access was restricted for
security measures. Onsite HIV test results were offered
to pregnant women free of charge, and positive cases
were enrolled for PMTCT services according to national
guidelines.
Role of funding source
The Centers of Diseases Control and Prevention (CDC)
provided technical support in the study design, result in-
terpretation, and thoroughly reviewed the paper for pub-
lication. The local team conducted data collection, data
analysis, writing of the report, and initiation of scientific
manuscript for publication.
The World Health Organization (WHO) and the
United States President’s Emergency Fund for AIDS Re-
lief (PEPFAR) had no direct involvement in the study
design, data collection, data analysis, result interpretation,
reporting and decision for publishing.
Results
Nationwide, 93.2% of the HIV-SSS sample size was ob-
tained. The South region did not reach the sample size
due to rejection of samples or of data collection sheets
for non-conformity.
Sociodemographic characteristics of the enrolled
antenatal care attendees
A total of 6521 ANC1 attendees were enrolled in the
study, half (49 · 3%) of them were young (aged 15–24),
with up to 75% aged below 30 years (Table 2).
83 · 6% of surveyed pregnant women attended school,
with 75 · 3% at a primary or secondary level, against 8 ·
3% at a university level (Table 3). Half of the ANC1 at-
tendees were housewives (49 · 7%), whereas 14 · 2% and
33% were students and employees, respectively.
PMTCT HIV testing and SSS NRL results
Overall, the rate of HIV testing acceptance in routine
PMTCT was 99 · 1% and all samples were tested both at
the PMTCT-SL and at the NRL; with 99 · 6% good labora-
tory practices for HIV testing at the level of PMTCT-SLs.
According to PMCTCT-SL HIV testing results, 47 women
samples were tested indeterminate, 417 had missing re-
sults; resulting to a total of 6056 conclusive results
(positive or negative) at the PMTCT-SLs. Using the tie-
breaker (Oraquick), all samples tested at the NRL got a
conclusive result (i.e. reported as positive or negative),
resulting to a total of 6103 samples (6056 + 47) consid-
ered in the final dataset for comparative analysis be-
tween PMTCT-SL and the NLR, considering the NRL
results as the reference standard.
Rate of HIV positivity at the PMTCT site laboratories
The general rate of HIV was 6 · 4% (5 · 7% rural versus
6 · 9% urban) based on PMTCT-SLs, with regional dispar-
ities, ranging in rural settings from 1 · 9 to 9 · 9% (Far
North-South) and in urban settings from 3 · 6 to 12 · 7%
(West-Centre). In summary, PMTCT site laboratories
generally underestimated HIV prevalence compared to
prevalence estimates from the NRL (6 · 46% versus 7 · 18%,
respectively Table 4).
Sensitivity and specificity of PMTCT site laboratories in
terms of HIV testing
Nationwide, the following intrinsic performance of
PMTCT-SLs was recorded: a sensitivity of 81 · 2% (from
58 · 8% in the South, to 100% in the West region) and a
specificity of 99 · 3% (from 98 · 8% in the South-west and
Littoral, to 100% in the Centre region). In terms of geo-
graphical location, rural settings had a sensitivity of 76 ·
5% and a specificity of 99 · 2%, while urban settings had
a sensitivity of 84 · 0% and specificity of 99 · 4%. A re-
gional comparison placed the West region with the high-
est performance as well as the only region with an
acceptable sensitivity (sensitivity of 100% and specificity
of 99 · 7%); followed by the Far-North (sensitivity of
93 · 1% and specificity of 99 · 2%) and the North-West
(sensitivity of 90 · 2% and specificity of 99 · 3%) regions.
In terms of extrinsic performance, performance of
Table 1 Calculation of intrinsic and extrinsic performances of
HIV testing by PMTCT site laboratories
National Reference Laboratory (NRL SSS-HIV test)
PMTCT sites results HIV+ HIV− Total
Test + a b a + b
Test− c d c + d
Total a + c b + d a + b + c + d
ReferenceHIV Prevalence¼100 aþcaþbþcþd
Sensitivity ¼ 100 aaþc
Positive Predictive Value ¼ 100 aaþb
PMTCT HIV rate ¼ 100 aþbaþbþcþd
Specificity ¼ 100 dbþd
NegativePredictiveValue ¼ 100 dcþd
Billong et al. BMC Infectious Diseases  (2017) 17:3 Page 4 of 11
PMTCT-SLs reported a national PPV of 88 · 8%, with
84 · 4% in rural and 91 · 5% in urban settings; a national
NPV of 98 · 2%, with 98% in rural and 98 · 3% in urban
settings. An intersection analysis between intrinsic and
extrinsic performances is showed in Fig. 2 (Table 5).
Performances in HIV testing between rural and urban
settings showed a statistically significant difference (p <
0 · 0001) in the rate of positive-HIV cases obtained from
routine-PMTCT rapid testing (6 · 4% positivity rate: 388/
6103) against results of the NRL (7 · 1% positivity rate:
431/6103) results. By geographical location, statistically
significant differences (p < 0 · 0001) were observed when
comparing PMTCT rapid testing in rural settings (5 · 6%
positivity rate: 144/2560) to that of their corresponding
NRL results (6 · 3% positivity rate: 162/6103), and when
comparing PMTCT rapid testing in urban settings (6 ·
9% positivity rate) to that of the NRL (7 · 1% positivity
rate).
Assessment of indeterminate results both at the PMTCT-
SLs and at the NRL
Of the 47 indeterminate results recorded at the
PMTCT-SLs after test 1 and test 2, referred to the NRL
for tiebreaking, 68 · 0% (32/47) of the samples were from
urban vs. 31 · 9% (15/47) from rural settings. At NRL, 7
(14 · 9%) of these indeterminate results were positive, 32
(68 · 0%) were negative, and 9 (19 · 1%) remain indeter-
minate after test 1 and test 2. Tiebreaker on these 9 per-
sisting indeterminate samples showed all were negative
(see Additional file 1: Table S1). Overall, HIV indeter-
minate results from PMTCT-SLs were 14 · 9% (7/47)
positive results vs. and 85 · 1% (40/47) negative.
At the NRL, a total of 36 indeterminate results were
recorded after test 1 and test 2. All 36 samples were then
tested with the tiebreaker, and revealed a total of 02 (5 ·
6%) positive and 34 (94 · 4%) negative (see Additional file
2: Table S2).
As expected, indeterminate results were lower at the
NRL (36) vs. PMTCT-SLs (47). In both contexts, inde-
terminate results were mostly driven by false reactivity
of test 1 (94 · 4% at NRL vs. 85 · 1% at PMTCT-SLs).
Discussion
The overall goal of our study was to assess the feasibility
of using routine PMTCT HIV testing data for HIV-SSS
among ANC attendees in Cameroon. HIV test results
were compared between routine PMTCT HIV testing
and testing done at NRL for SSS.
Although the rate of HIV testing acceptance was high
and compliance to the national HIV testing algorithm
Table 2 Distribution of ANC1 attendees according to age and PMTCT site localization (N = 6521)
URBAN RURAL Overall
Age range Number % Number % Number %
<25 years 1461 52 · 41% 1756 47 · 04% 3217 49 · 33%
15–19 years 585 20 · 98% 608 16 · 30% 1193 18 · 29%
19–24 years 876 31 · 43% 1148 30 · 75% 2024 31 · 04%
≥25 years 1326 47 · 59% 1978 52 · 96% 3304 50 · 67%
25–29 years 672 24 · 17% 1004 26 · 84% 1676 25 · 70%
30–34 years 407 14 · 58% 634 16 · 99% 1041 15 · 96%
35–39 years 173 6 · 18% 268 7 · 20% 441 6 · 76%
40–44 years 69 2 · 48% 68 1 · 82% 137 2 · 10%
45–49 years 5 0 · 18% 4 0 · 11% 9 0 · 14%
Total 2787 100 · 00% 3734 100 · 00% 6521 100 · 00%
Legend. numbers and percentages in bold represent the highest sub-populations of study participants
Table 3 Distribution of ANC1 attendees according to educational level and site localization (N = 6521)
Educational Level Area of Residence
Rural Urban Total
Number % Number % Number %
None 606 21 · 73% 465 12 · 47% 1071 16 · 42%
Primary 1089 39 · 08% 1230 32 · 94% 2319 35 · 56%
Secondary 997 35 · 74% 1595 42 · 73% 2592 39 · 75%
University 95 3 · 45% 444 11 · 85% 539 8 · 27%
Total 2787 100 · 00% 3734 100 · 00% 6521 100 · 00%
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was satisfactory (99 · 6% good laboratory practices), there
were poor performances in nine out of the ten regions
of Cameroon, translated by significant disparities be-
tween HIV positivity rates from routine PMTCT HIV
testing and the NRL (p = 0 · 002). These data indicate
that PMTCT HIV testing will need significant strength-
ening and quality assurance as Cameroon transitions to
using routine PMTCT data for surveillance. The current
level of laboratory quality assurance for HIV screening
in the PMTCT program remains very low.
Practically, the capacity of routine PMTCT HIV test-
ing to correctly identify HIV-positive pregnant women
(sensitivity) was only 81 · 2%, meaning that about 19% of
HIV-infected women are wrongly declared HIV sero-
negative at the PMTCT-SL and are thereby mistakenly
excluded from PMTCT care, indicating high risk of poor
clinical outcomes and HIV vertical transmission. Regions
with lowest sensitivities include the South and littoral re-
gions. Interestingly, the probability of a pregnant woman
who received a seropositive HIV result at the PMTCT-
SL, to be truly positive (PPV) is 89%, implying that 11%
of pregnant women declared HIV seropositive at the
PMTCT site laboratory are not infected in principle,
those are wrongly declared HIV-positive with unneces-
sarily enrolled for PMTCT care. As rural settings experi-
enced poorer performance, it is interventions should
mostly target these settings that mainly remain at the
primary healthcare levels.
In contrast to intrinsic performance, the capacity of
each PMTCT-SL in delivering HIV negative results ap-
peared satisfactory (99 · 3% overall). Of note, only one
region (West) attained the required target both for the
sensitivity and specificity; while the South region recorded
the poorest intrinsic performance. Our study indicates an
overall tendency of PMTCT data in underestimating the
epidemiological burden, which raises important program-
matic concerns in a vision of MTCT elimination, since
HIV-infected mothers out of care are major reservoirs for
onwards vertical transmission [19, 20]. The sensitivity of
81% suggests that about two out of ten HIV-positive
(according to NRL testing) ANC1 attendees would be
diagnosed negative by PMTCT HIV screening and
could transmit HIV vertically. Therefore, the estimated
total number of HIV-infected pregnant women who would
be missed each year nationwide is 182,588 (ANC1) × 7 · 1%
(HIV positivity rate) × 20% (false negative) = 2,593
(HIV-infected women left out of care). Therefore, about
2,000–3,000 HIV-infected pregnant women remain un-
diagnosed, indicating consistent risks of MTCT, due to
inaccurate diagnosis. In spite of the high specificity
(99 · 3%), the 0 · 7% pregnant women receiving a false
positive HIV result translates into a national estimate of
182,588 (ANC1 per year) × [1–0 · 071] (i.e. 1−positivity
rate) × 0 · 7% (false positive) = 1,188 ANC1 with a false
positive HIV result every year. Thus, over a thousand of
women would be wrongly receiving ART every year, es-
pecially with the advent of PMTCT option B+ rollout.
This indicates misused resources in an era of poor ART
coverage.
For corrective measures, it may be useful to study on-
site factors associated with laboratory performance. Well
performing sites (i.e. West region) could share best
Fig. 2 Intersection Analysis of intrinsic and extrinsic performances. Intersection analysis of performance. HIV: Human immunodeficiency virus; NRL:
National reference laboratory; PMTCT: prevention of mother to child transmission
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practices to poorly performing sites. The high rate of
HIV testing acceptance (favored by the Opt-Out ap-
proach in ANC/PMTCT pre-counseling and free screen-
ing) excluded possibility of differential HIV prevalence
among refusals and accepters, thus limiting bias in
PMTCT HIV prevalence estimates [11]. Except for few
controversies [12, 21], HIV testing acceptance is often
voluntary in African settings [7–11, 13–15, 22–24]. In
Mozambique, a sub-Saharan African country with com-
parable socio-economical realities to Cameroon, using
matched PMTCT and SSS results also showed gaps in
the quality of PMTCT HIV testing [16]. In addition to
previously concordant studies, a major strength of our
survey is the large sample size and the high level of na-
tional representativeness (regional, rural, urban).
Our major limitation was the difficulties in further ex-
ploring discrepant results between the PMTCT-SLs and
NRL. Nonetheless, these discrepancies are presumed to
be errors in site-level PMTCT testing, since this testing
is done by a varied cadre of technicians, in sometimes
sub-optimal environmental circumstances, and with lim-
ited quality checks (as shown by varying quality systems
in place). In contrast, testing at NRL is done by a small
group of highly trained, highly supervised technicians in
a well-controlled environment, and was subjected to ex-
tensive quality control checks. Even if it is concluded
that discrepancies were the result of errors at site labora-
tories, the specific problems were not identified. Errors
may occur at the levels of sample labeling/registration
(pre-analytical phase), sample testing (analytical) and re-
sults interpretation/delivery/recording (post-analytical
phase) phases. Identifying these sources of errors would
enable relevant recommendations for corrective measures.
The poor quality of data in ANC register also stands a po-
tential source of errors, though this was generally solved
by supervision. Therefore, the poor concordance between
PMTCT-SL and ANC HIV-SSS is likely attributed to poor
QA system on-site. Implementing a reliable HIV surveil-
lance system based on routine PMTCT program data
warrants continuous training, evaluation, mentorship,
and regular supervision of PMTCT sites in LICs like
Cameroon.
Interestingly, poor sensitivity of field rapid HIV testing
was reported in the South-African PMTCT program using
three different rapid tests (94.5% with First Response,
90.2% with Pareekshak, and down to 87.5% with Standard
Diagnostic) [25], implying that even with adequate QA
system, rapid testing results could be variable, with
higher rate of HIV indeterminate results from our
urban PMTCT-SLs compared to their rural peers. Of
note, indeterminate results were mostly driven by false
reactivity of test 1, thus underscoring the necessity of
confirming all reactive results after test 1 [25, 26]. This
also prompts the need for regular validation, through
diagnostic performance evaluation, of rapid tests used
in LICs facing similar challenges in the national testing
algorithm (against reference standards: fourth generation
ELISA, Western Blot and/or molecular diagnostics for
confirmation), for an improved evidence-based policy on
HIV testing in such settings.
Conclusion
Despite the high acceptance rate of HIV testing, sensitivity
of HIV testing at PMTCT-SL remains poor, indicating the
inability to use PMTCT for routine HIV-SSS in Cameroon.
These substantial gaps in quality assurance, within routine
PMTCT HIV testing pipeline, warrant robust laboratory
strengthening measures in an era of transition to using rou-
tine PMTCT data for ANC SSS. Even though PMTCT-SL
seem highly qualified in screening for uninfected women,
sub-optimal performance in detecting HIV-infected preg-
nant women has important programmatic implications on
the effort to eliminate MTCT. Thus, as Cameroon transi-
tions to using PMTCT data for HIV-SSS, strengthening
routine HIV testing through training, mentorship,
supervision and consistent QA program, is crucial prior to
provide robust data for surveillance and for optimal
MTCT elimination.
Additional files
Additional file 1: Table S1. HIV NRL results of indeterminate results at
PMTCT-SLs. (DOC 37 kb)
Additional file 2: Table S2. Tiebreaker of the NRL indeterminate
results. (DOC 35 kb)
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